Object. Because of their critical location adjacent to brain, cranial nerve, and vascular structures, petroclival meningiomas remain a clinical challenge. The authors evaluated outcomes in 168 patients with petroclival meningiomas who underwent Gamma Knife surgery (GKS) during a 21-year interval.
B
ecause of their proximity to critical CN, brainstem, and vascular structures, petroclival meningiomas remain a management challenge to both patients and their physicians. Although advances in cranial base surgery have improved outcomes, the risk of significant morbidity remains. 2, 4, 18, 22, 25, 28, 31 The role of stereotactic radiosurgery for newly diagnosed, incompletely resected, or recurrent tumors has gained increasing acceptance over the past decade. [12] [13] [14] [15] [16] [17] 23, 27, 33, 36 The firm integration of radiosurgery into the management of such difficult meningiomas requires tumor control that is long term and late treatment-related complications that are rare. The goal in the present report, which could be considered a follow-up to a previous article, 33 is to define the extended-term imaging response and clinical outcomes after radiosurgery.
Methods
This retrospective analysis was performed with the approval of the University of Pittsburgh Institutional Review Board. The records and imaging results were prospectively collected and then retrospectively and independently reviewed by 3 neurosurgeons who had not participated in the care of these patients.
Patient Population
During a 21-year interval, 168 patients underwent GKS for skull base meningiomas originating in the region between the petrous apex and the upper two-thirds of the clivus. Some tumors extended into the middle cranial fossa, cavernous sinus, or prepontine space. All tumor components were included in the imaging-defined radiosurgical treatment volume. Fourteen additional patients who had undergone GKS for petroclival meningioma during this same interval were eliminated from Long-term control of petroclival meningiomas through radiosurgery further analysis because of insufficient follow-up ( Fig.  1) . Forty-four (26%) were male and 124 (74%) were female. The mean patient age was 57 years. At the time of prior surgery, 3 patients were found to have atypical meningiomas (WHO Grade II) and 2 had anaplastic meningiomas (WHO Grade III). Gamma Knife surgery was performed as the initial, or primary, therapeutic modality (97 patients), after prior subtotal resection (32 patients), or when recurrent tumor developed after an initial complete resection (39 patients).
Five patients had multiple intracranial tumors; 3 had neurofibromatosis Type 2, 1 had multiple endocrine neoplasia Type I syndrome, and 1 patient had multiple atypical meningiomas. Five patients had meningiomas related to prior fractionated radiation therapy: 2 had radiation for a pituitary adenoma, 2 had prior tonsillar irradiation, and 1 underwent whole-brain fractionated radiation for metastatic thyroid carcinoma. Prior fractionated radiation therapy and radiosurgery performed elsewhere had failed in 2 patients each.
Symptoms and Signs
The most common presenting symptom in both the primary and adjuvant-treated groups was facial sensory dysfunction (pain, numbness, or paresthesias), which was present in 64 patients (38%). Other symptoms included balance disorders in 49 (29%), double vision in 47 (28%), hearing loss and/or tinnitus in 47 (28%), and headaches in 18 (11%; Table 1 ). The most common neurological deficits at the time of GKS were neuropathies of CNs V (69 patients [41%]), VIII (57 patients [34%]), VI (51 patients [30%]), and VII (37 patients [22%]). Seventy-one patients had multiple cranial neuropathies. In 55 patients multiple cranial neuropathies were related to prior resection. Patients who had undergone prior resection were more likely to have CN deficits at the time of GKS than were patients who underwent radiosurgery as their primary treatment (p < 0.001). Cerebellar ataxia was detected in 18 patients (11%) and hemiparesis in 12 (7%).
Indications for Radiosurgery
In this study GKS was performed in patients with residual or recurrent tumors after previous resection and in those with newly diagnosed symptomatic tumors. All patients treated with GKS had evidence of tumor growth during serial observation. Contraindications to primary radiosurgery included larger tumor volumes (usually with an average diameter > 3.5 cm associated with symptomatic mass effect leading to headache, increased intracranial pressure, and rapidly progressive brainstem or cerebellar dysfunction), elderly patients with incidentally discovered tumors, and atypical imaging features that warranted early histological diagnosis.
Radiosurgical Technique
Radiosurgery was performed under local anesthesia with mild intravenous sedation (midazolam and fentanyl) as necessary. Various models of the Leksell Gamma Knife (U, B, C, and 4C, Elekta Instruments, Inc.) were used. After applying the stereotactic frame, high-resolution, volume-acquisition stereotactic MR images were obtained. Before 1991 we performed radiosurgery using stereotactic CT guidance. Image-integrated isodose plans were created to enclose the irregular tumor borders by using computer software (Kula or GammaPlan). The dose received by adjacent critical structures was determined, and selective beam blocking was used if necessary to enhance selectivity by restricting the dose falloff in adjacent structures. 29 The maximal and tumor margin radiation doses were selected by the radiosurgery team consisting of a neurosurgeon, radiation oncologist, and medical physicist. , and a median radiation dose of 13 Gy was delivered to the tumor margin. Radiation doses were prescribed to the 50% isodose volume for 156 tumors (93%). After radiosurgery, patients were discharged home within 3-24 hours.
Follow-Up Studies
Follow-up imaging studies were requested at 6 months and 1, 2, 4, 8, and 12 years after radiosurgery, and at 4-year intervals thereafter. Imaging was performed at other intervals if new neurological signs or symptoms were detected. The median imaging follow-up was 64 months (range 3-204 months). Twenty-two patients (13%) had an imaging follow-up < 1 year, 53 (32%) between 1 and 5 years, 62 (37%) between > 5 and 10 years, and 31 (18%) > 10 years. Follow-up MR images were compared with the intraoperative images, and tumor dimensions were measured in the axial, sagittal, and coronal planes. Partial regression (PR) was defined as > 50% shrinkage of the tumor volume, stable disease (SD) as < 25% change in tumor volume, and progressive disease (PD) as > 25% increase in tumor volume. With regard to tumor progression, patients were considered to be progression free only at their last radiological follow-up. Tumor progression after radiosurgery was classified as inside the previous radiosurgical treatment volume, outside the previous radiosurgical volume, or mixed (inside and outside, including marginal tumor progression).
Clinical follow-up was conducted at our center (59% of patients) or by direct telephone contact by 1 of us (T. J. F., 21%), or by the referring physician (10%). The median clinical follow-up interval was 72 months, and the longest follow-up was 254 months. Nineteen patients (11%) had a clinical follow-up < 1 year, 50 (30%) between 1 and 5 years, 58 (34%) between > 5 and 10 years, and 41 (24%) > 10 years.
Statistical Methods
For statistical analysis, we constructed Kaplan-Meier plots for OS and PFS using the dates of diagnosis, first surgery, first stereotactic radiosurgery, follow-up imaging, and death or last follow-up. The time to tumor progression was coded as the time that an imaging study showed progression-that is, the time of documentation of tumor growth-and with regard to tumor progression, patients were considered to be progression free only at their last radiographic follow-up. Progression-free survival and OS times were calculated from the day of the first GKS procedure by using the Kaplan-Meier method. Univariate comparisons between groups were performed using the log-rank test, with p < 0.05 set as the level of significance. We performed multivariate analysis using the Cox proportional hazards model, with p < 0.10 as significant. Standard statistical processing software (Statistical Package for Social Sciences, version 15.0, SPSS, Inc.) was used.
Results

Overall Clinical and Imaging Response
After radiosurgery, neurological symptoms or signs improved in 44 patients (26%), remained stable in 98 (58%), or eventually worsened (either due to progression of initial symptoms or development of new neurological symptoms) in 26 (15%), as shown in Table 1 . Tumor growth control was achieved in 152 patients (90%), and 16 patients eventually demonstrated progressive tumor growth at a median interval of 54 months (Table 2) . Eight patients had repeat radiosurgery, 4 underwent delayed resection, and 4 had fractionated radiation therapy. The mean PFS for the entire study population (168 patients) was 184.1 months (95% CI 172. 5-195.8 ). The overall 5-and 10-year PFS rates were 91 and 86%, respectively. In patients with a minimum of 2 years of follow-up (median follow-up 72 months), the 5-and 10-year PFS rates were 94 and 86%, respectively. The tumor control rate in the primary GKS group was 95%, while the adjuvant-treated WHO Grade I group had a tumor control rate of 91%. All patients with atypical (WHO Grade II, 3 patients) and anaplastic meningiomas (WHO Grade III, 2 patients) eventually experienced clinical deterioration, which was associated with imaging evidence of tumor progression at a median interval of 36 months after GKS. Tumor recurrence in these 5 patients was due to irradiated tumor pro- 
Outcomes in Primary Radiosurgery and Adjuvant-Treated WHO Grade I Groups
The response rates in the primary group and adjuvanttreated WHO Grade I group were similar (Tables 1 and 2) . Ninety-seven patients had radiosurgery as their primary therapeutic modality; 26 reported symptomatic improvement, 59 remained unchanged, and 12 were symptomatically worse after GKS (median follow-up of 76, 71, and 41 months, respectively). Of the 12 patients whose symptoms progressed, a variety of causes were noted. Four cases were due to tumor progression, 2 required CSF diversion for hydrocephalus, 1 had glycerol rhizotomy for trigeminal neuralgia, and 1 had delayed tumor resection. The patient who underwent delayed resection continued to have intractable facial pain and eventually committed suicide. The remaining 4 patients with new symptoms were medically treated for deteriorating balance (2 patients), vocal cord paresis resulting in aspiration pneumonia (1 patient), or new-onset headaches (1 patient). Partial tumor regression was noted on follow-up neuroimaging in 49% of patients (median follow-up 72 months), SD in 46% (median interval 27 months), and PD in 5% (median follow-up 53 months). Tumor progression was within the GKS-treated volume in 2 patients, both inside and outside in 2 patients, and outside the radiosurgical tumor volume in 1 patient. One patient had evidence of tumor progression involving the sphenoid sinus despite symptom control.
Sixty-six patients had adjuvant GKS after resection of a WHO Grade I meningioma; 18 reported an improvement, 39 no change, and 9 eventual worsening after GKS (median follow-up of 89, 84, and 24 months, respectively; Table 1 ). Four patients experienced additional symptoms due to tumor progression, 4 underwent CSF diversion for hydrocephalus, and 1 patient had new-onset focal seizures (this patient with a history of neurofibromatosis Type II required multiple craniotomies for meningiomas). Partial tumor regression was noted on follow-up neuroimaging in 47% of patients (median follow-up 80 months), SD in 44% (median follow-up 77 months), and PD in 9% (median follow-up 54 months). Tumor progression was detected in 2 symptomatically stable patients on routine surveillance imaging.
Although patients with WHO Grade I meningiomas confirmed on prior surgery underwent GKS for significantly larger tumor volumes (mean tumor volume 9.1 cm 3 ) compared with patients in the primary radiosurgery group (mean tumor volume 7.5 cm 3 , p = 0.035), no difference was detected in PFS (p = 0.614). For both of these groups of patients (163 patients), the 5-and 10-year PFS rates were 93 and 90%, respectively (Fig. 2) . In patients with a minimum of 2 years of follow-up (122 patients, median follow-up 80 months), the 5-and 10-year PFS rates were 95 and 89%, respectively. Tumor control (PR and SD) correlated well with symptom control (improvement and stable clinical condition) for both subgroups. Tumor progression was significantly associated with symptomatic deterioration after radiosurgery (p < 0.0001, Fisher exact test). Patients with symptom worsening were more likely to have larger tumors than those with symptom control (p = 0.04, Mann-Whitney U-test). Tumor volumes ≥ 8 cm 
Subgroup Analysis of Patients With an Extended FollowUp
Thirty-one patients had at least 10 years of followup after GKS. The distribution of tumor volumes treated were < 5 cm (1 lesion). Sixteen patients had PR, 14 had SD, and 1 pa- tient required repeat GKS for delayed tumor progression at 125 months. An additional patient with a confirmed atypical meningioma underwent repeat GKS for tumor progression at 9 years after the initial GKS. He required further GKS 2 years later for an enlarging convexity meningioma (12 years after his original craniotomy), by which time the petroclival tumor had markedly regressed (Fig. 4) . Eleven patients noticed an improvement in their initial symptoms, and 18 had no change. One patient had new-onset seizures, and another had increased facial pain (which was managed with medication).
Adverse Effects of Radiation
Adverse radiation effects, defined as the presence of clinical or neurological deterioration in the absence of tumor growth on serial MR images, occurred in 14 patients (8%). New or exacerbated existing cranial neuropathies (CNs V and IX/X) developed in 3 patients (2%). Worsening cerebellar symptoms developed in 2 patients, and new-onset seizures and headaches developed in 1 patient each. Four patients (2%) demonstrated new signal hyperintensity in the brainstem, cerebellum, or temporal lobe on T2-weighted or FLAIR MR imaging sequences; however, symptoms developed in none of these patients.
Risk of Hydrocephalus
Seven patients (4%, mean age 65 years) had symptomatic hydrocephalus at a median interval of 7 months after GKS, and all responded to CSF diversion. Five of had undergone a prior resection and 2 had primary radiosurgery. Shunt-related sepsis occurred in 1 patient, who ultimately died of septicemia. One patient treated for a recurrent atypical meningioma had a tumor-related intracerebral hemorrhage 1 week after repeat GKS (38 months after the initial GKS). This patient eventually required shunting to manage the posthemorrhagic hydrocephalus. 
Survival After Radiosurgery
Twenty-five patients, whose mean age at the time of radiosurgery was 72 years (range 52-81 years), died at a median follow-up of 75 months after GKS. The cause of death was not known in 8 patients. Nine patients died as a direct result of tumor progression or its side effects (3 of whom had atypical or malignant tumors), including 1 patient who committed suicide because of intractable facial pain, 1 who suffered respiratory arrest due to a longstanding seizure disorder, and 1 as a result of shunt sepsis. Three patients died of another unrelated neoplastic process (multiple myeloma, renal cell carcinoma, and breast carcinoma). The remaining 5 patients died of unrelated (respiratory and cardiac) medical illnesses.
The mean patient survival for the entire study population (168 patients) was 198.9 months (95% CI 178.8-219.1), and the 5-and 10-year OS rates were 95 and 78%, respectively. When patients with histologically confirmed atypical or anaplastic meningiomas are excluded from analysis (5 patients), the 5-and 10-year OS rates were 96 and 81%, respectively (Fig. 5) . There was no significant difference in survival rates between patients treated with primary GKS and adjuvant-treated patients with WHO Grade I lesions. A patient age > 55 years (p = 0.02, logrank test) and a tumor volume > 6 cm 3 (p = 0.03, log-rank test) were significantly associated with shorter survival.
Discussion
The natural history of petroclival meningiomas suggests that most tumors will eventually grow. 35 In a retrospective study of 21 conservatively treated patients with a median follow-up of 85 months, radiologically demonstrated tumor growth was observed in 76% of cases. Furthermore, 63% of patients with growing tumors had evidence of functional deterioration. These observations suggest that in the majority of cases, with the possible exception of those involving an advanced age and significant medical comorbidity, petroclival meningiomas should be treated. Refinements in the microsurgical approaches to petroclival meningiomas have significantly reduced perioperative morbidity and mortality rates and improved GTR rates. 2, 3, 22, 25 Even with GTR, however, a risk of tumor recurrence persists since total resection of the lesion and its meningeal base is often impossible. Natarajan et al. 22 have reported on their series of 48 petroclival meningiomas after complete resection: the recurrence-free rate was 100% at 3 years, 92.7% at 7, and 85% at 12. These rates are consistent with the recurrence prediction following a Simpson Grade 1 resection, that is, 9% recurrence rate at 10 years. 30 The critical location of petroclival tumors often precludes complete excision. The efficacy and safety of stereotactic radiosurgery has led some surgeons to forego attempts at complete resection in favor of tumor debulking followed by adjuvant radiosurgery. 3 Some patients select radiosurgery as a primary therapeutic option to reduce the risks associated with attempted resection. Although there is increasing evidence of the long-term tumor control provided by radiosurgery for meningiomas, [12] [13] [14] [15] [16] [17] 23, 27, 33, 36 detailed outcome analysis at longer intervals is necessary. 6, 20 In a series of skull base meningiomas that progressed despite various types of radiation delivery, delayed progression was noted even after 14 years. 6 In a retrospective review of patients with meningiomas treated using fractionated radiation therapy over a 20-year period, 56% of patients experienced serious adverse radiation effects. 19 The complications encompassed neuropsychological and neurological motor and sensory deficits and were severe enough to cause hospitalization or a major change in lifestyle. However, recent improvements in fractionation techniques suggest that intensity-modulated radiation therapy may be a reasonable therapeutic option for larger skull base meningiomas. In a series of 94 patients with complex-shaped meningiomas with a median target volume of 81.4 cm 3 , local control rates of 93.6% were achieved at a median follow-up of 4.4 years. 21 In addition, Clark et al. 5 have demonstrated that stereotactic intensitymodulated radiation therapy appears to significantly improve dose sparing of the brainstem and temporal lobe, although no such benefit was found for the optic nerve or pituitary gland.
Given the natural history of petroclival meningiomas, 35 our results indicated that GKS leads to longterm tumor control and minimal treatment-related morbidity. Overall, tumor control was confirmed in 91% of patients at 5 years and 86% at 10 years, and the tumor control rate was 90% at 10 years when higher-grade tumors were excluded. Thus, our data and those of others show that in smaller-volume meningiomas stereotactic radiosurgery can provide results similar to a Simpson Grade 1 resection. 16, 24 In contrast, surgically confirmed atypical or anaplastic meningiomas eventually progressed at a median interval of 36 months after radiosurgery. This observation is in keeping with the higher recurrence rate of atypical and anaplastic meningiomas after either radiosurgical or initial microsurgical management. 9 Huffmann et al. 11 have found a recurrence in 40% of patients with atypical meningiomas between 18 and 36 months after GKS, while Stafford et al. 32 have reported 5-year local control rates of 93, 68, and 0% for benign, atypical, and malignant subtypes, respectively. Similarly, after initial GTR atypical meningiomas have a high recurrence rate. In a series of 108 atypical meningiomas described by Aghi et al., 1 28% of tumors recurred 3-144 months (mean 36 months) after GTR. Recurrences caused numerous reoperations per patient and shortened survival. These authors also found that patients who underwent immediate postoperative radiation had a lower recurrence rate (8 received postoperative radiation without recurrence [p = 0.1]). In our experience, tumor volume and male sex also were significantly associated with tumor progression. Patients with a tumor volume ≥ 8 cm 3 were more likely to have symptomatic tumor progression. Although the reason that male sex was also associated with a higher risk of both symptomatic and tumor progression is not known, Kollova et al. 15 have reported a similar relationship. Moreover, DiBiase et al. 7 have found in 162 cases of benign meningiomas managed with GKS that the cases in male patients had a worse prognosis. While a difference in hormone receptors between sexes is suspected, the true reason for an increased rate of progression in men is unknown.
Twenty-six percent of our patients had symptomatic improvement and 58% had stable symptoms following GKS. Most patients who improved did so over months or even years. In fact, so gradual was the improvement that some patients had difficulty remembering their initial symptoms. Of the 26 patients who experienced clinical deterioration, 13 (50%) had tumor progression confirmed at the time of follow-up imaging. Asymptomatic tumor progression occurred in 3 patients. Extracranial tumor extension into adjacent skull base regions, such as the sphenoid sinus, occurred in 2 patients.
The overall risk of complications in this series was low; new symptoms without evidence of tumor progression developed in 13 patients. The low risk of new CN dysfunction has also been noted in other radiosurgical outcome studies. 14, 23, 34 In fact, as reported by Han et al., 8 existing cranial neuropathy may even improve in up to 45% of patients. Huang et al. 10 have demonstrated that 57% of patients had improvement in their trigeminal pain after GKS for a benign tumor (12 of 21 patients had a meningioma). The rate of pain control improved to 76% of patients when symptomatically recurrent cases involved treatment of the trigeminal nerve or ganglion as well. Potential mechanisms for this improvement include tumor regression relieving pressure on the nerve root and/or demyelination resulting in the blockade of ephaptic transmission. Other CNs also seemed to be relatively resistant to radiation injury, especially motor nerves. Our findings, in general, support the observation of low morbidity as well as the potential for neurological improvement following GKS. The management of trigeminal pain or neuropathy is frequently difficult in such patients because of the intimate contact between the tumor and the nerve. We have performed subsequent radiosurgery if the nerve could be distinguished on MR imaging. As an alternative we have performed percutaneous glycerol rhizotomy in select patients.
While the risk of CN morbidity in our series was low, the incidence of delayed-onset symptomatic hydrocephalus was higher than that reported for other skull base tumors. 26, 34 Roche et al. 26 have found that hydrocephalus developed in 1% of patients who underwent GKS for vestibular schwannomas and that all patients required CSF shunting. Age at the time of treatment and tumor volume were higher in patients who required shunts compared with those in the entire treated population. The mean interval between GKS and CSF shunting was 14.8 months (range 4-31 months). In our series tumor volume was significantly associated with the risk of hydrocephalus (13.1 cm 3 in the shunt group vs 7.4 cm 3 in those without hydrocephalus, p = 0.01). The interval to the development of hydrocephalus was shorter in our series (median interval 7 months). It is important to note that most patients had undergone prior resection, with the potential for arachnoidal adhesions also contributing to CSF flow obstruction.
Conclusions
Our long-term outcomes assessment would have been enhanced if all patients had been able to participate in face-to-face follow-up examinations and clinical imaging at our center. Since many patients live significant distances from our center, we had to rely on assessments provided by the patients' current physicians or from direct telephone contact. The long-term goals of radiosurgery are to control tumor growth and minimize the risks of treatment. We believe that our data provide additional long-term evidence that radiosurgery is a safe and effective strategy that should be used for newly diagnosed or residual petroclival meningiomas. The 10-year tumor control rate is similar to that expected after a Simpson Grade 1 resection of a histologically benign meningioma.
